Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3′-deoxy-3′-[18F]fluorothymidine in preclinical tumor models

被引:0
作者
Seung Jin Lee
Hye Young Kang
Seog Young Kim
Jin Hwa Chung
Seung Jun Oh
Jin-Sook Ryu
Sung-Bae Kim
Jong Soon Kang
Song-Kyu Park
Hwan Mook Kim
Myung-Hwa Kim
Dae Hyuk Moon
机构
[1] University of Ulsan College of Medicine,Institute for Innovative Cancer Research
[2] Asan Medical Center,Department of Nuclear Medicine
[3] University of Ulsan College of Medicine,Department of Oncology
[4] Asan Medical Center,undefined
[5] University of Ulsan College of Medicine,undefined
[6] Asan Medical Center,undefined
[7] Bioevaluation Center,undefined
[8] Korea Research Institute of Bioscience and Biotechnology,undefined
[9] Drug Discovery Laboratory,undefined
[10] R&D Center,undefined
[11] Jeil Pharmaceutical Co.,undefined
[12] Ltd.,undefined
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2011年 / 38卷
关键词
Anti-tubulin agent; JAC106; [; F]Fluorothymidine; Positron emission tomography;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1436 / 1448
页数:12
相关论文
共 171 条
[1]  
Jordan MA(2004)Microtubules as a target for anticancer drugs Nat Rev Cancer 4 253-265
[2]  
Wilson L(2009)Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance Mol Cancer Ther 8 2086-2095
[3]  
Perez EA(2004)Paclitaxel for non-small cell lung cancer Expert Opin Pharmacother 5 1771-1780
[4]  
Ramalingam S(2007)MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps Cancer Res 67 5865-5871
[5]  
Belani CP(2003)Mechanisms of Taxol resistance related to microtubules Oncogene 22 7280-7295
[6]  
Kasibhatla S(2010)Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer J Clin Oncol 28 3463-3471
[7]  
Baichwal V(2009)Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 2516-2522
[8]  
Cai SX(2007)HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 1496-1506
[9]  
Roth B(2008)MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer Mol Cancer Ther 7 1150-1155
[10]  
Skvortsova I(2005)Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer Ann Oncol 16 iv14-iv19